- Home
- PSF vs ADCT Comparison
PSF vs ADCT Comparison
Compare PSF & ADCT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- PSF
- ADCT
- Stock Information
- Founded
- PSF 2010
- ADCT 2011
- Country
- PSF United States
- ADCT Switzerland
- Employees
- PSF N/A
- ADCT N/A
- Industry
- PSF Investment Managers
- ADCT Biotechnology: Pharmaceutical Preparations
- Sector
- PSF Finance
- ADCT Health Care
- Exchange
- PSF Nasdaq
- ADCT Nasdaq
- Market Cap
- PSF 235.2M
- ADCT 241.0M
- IPO Year
- PSF N/A
- ADCT 2020
- Fundamental
- Price
- PSF $19.54
- ADCT $2.99
- Analyst Decision
- PSF
- ADCT Strong Buy
- Analyst Count
- PSF 0
- ADCT 5
- Target Price
- PSF N/A
- ADCT $7.75
- AVG Volume (30 Days)
- PSF 25.0K
- ADCT 694.8K
- Earning Date
- PSF 01-01-0001
- ADCT 05-14-2025
- Dividend Yield
- PSF 7.69%
- ADCT N/A
- EPS Growth
- PSF N/A
- ADCT N/A
- EPS
- PSF N/A
- ADCT N/A
- Revenue
- PSF N/A
- ADCT $75,817,000.00
- Revenue This Year
- PSF N/A
- ADCT $9.19
- Revenue Next Year
- PSF N/A
- ADCT $16.27
- P/E Ratio
- PSF N/A
- ADCT N/A
- Revenue Growth
- PSF N/A
- ADCT 10.49
- 52 Week Low
- PSF $16.00
- ADCT $1.05
- 52 Week High
- PSF $20.19
- ADCT $4.13
- Technical
- Relative Strength Index (RSI)
- PSF 55.65
- ADCT 75.65
- Support Level
- PSF $19.10
- ADCT $1.83
- Resistance Level
- PSF $19.62
- ADCT $2.35
- Average True Range (ATR)
- PSF 0.16
- ADCT 0.31
- MACD
- PSF 0.00
- ADCT 0.12
- Stochastic Oscillator
- PSF 77.33
- ADCT 93.03
About PSF Cohen & Steers Select Preferred and Income Fund Inc.
Cohen & Steers Select Preferred and Income Fund Inc is a diversified, closed-end investment company. The Fund's primary investment objective is high current income with capital appreciation as its secondary objective. The Fund invests at least of its Managed Assets in preferred and other income securities issued by U.S. and non-U.S. companies.
About ADCT ADC Therapeutics SA
ADC Therapeutics SA is a commercial-stage oncology-focused biotechnology company. It is involved in the development of antibody-drug conjugates for patients suffering from hematological malignancies and solid tumors. The company's FDA-approved and marketed product, ZYNLONTA (loncastuximab tesirine), is a CD19-directed antibody and alkylating agent conjugate indicated for the treatment of adult patients with relapsed or refractory large B-cell lymphoma after two or more lines of systemic therapy. In addition, it also has various other product candidates in its pipeline, such as ADCT-602, Claudin-6, PSMA, NaPi2b, and ASCT2. Geographically, the company generates maximum revenue from the United States, followed by Europe, the Middle East and Africa (EMEA).